

Curriculum Vitae

Personal Information

Name **DANILO**
Surname **DI BONA**

Phone +39 0881 736401 (office)

E-mail daniло.dibona@unifg.it;
daniлоdibona@yahoo.it (private)

Occupation Full Professor/MD

University of Foggia, Department of Medical and Surgical sciences, University Hospital–
Foggia, Italy

Training and qualifications

- 29/10/1996: Degree in Doctor of Medicine (110/110 with Honors) University of Palermo, Italy
- 1997: Licensed to practice the Profession of Physician-Surgeon
- 1997: Resident physician in Gastroenterology Unit - University of Palermo
- 1998-2000: Researcher at Department of Molecular Medicine University "La Sapienza" Rome, Italy
- 30/10/2001: Specialized in Clinical Pathology (50/50 with Honors) - University of Palermo
- 2001-2002: Resident physician in Gastroenterology Unit - University of Palermo
- 2002: Instructor of Pathology and Immunology in the School of Medicine and Surgery of the University of Palermo
- 2000-2002: Instructor of Gastroenterology in the Regional Course for family physicians
- 2005: PhD in Bio-Pathology - University of Palermo, Italy
- 2002-2006: Post-doc fellowships at the Italian National Council of Research (CNR), Institute of Immunology and Molecular Medicine
- 2006: Researcher at the Italian National Council of Research (CNR) (classified first in national competition #310.2.122/M.)
- 2007 to 2015: Resident physician at the Department of Immunohematology and Transfusion Medicine, University Hospital "Azienda Ospedaliera Universitaria – P. Giaccone", Palermo, Italy
- 2008-2010: Instructor of Pathology in the School of Medicine and Surgery of the University of Palermo
- 2016-2019: Assistant professor in Internal Medicine, Allergology and Clinical Immunology; University of Bari Aldo Moro, Bari, Italy
- 2019 to 2023: Associate professor in Internal Medicine, Allergology and Clinical Immunology; University of Bari Aldo Moro, Bari, Italy
- 2023 to date: Full professor in Internal Medicine, Allergology and Clinical Immunology; University of Foggia, Italy
- 2004 to date: Expert witness for Medical Claims Court.

Areas of research

Asthma, Immunology, immunopathology, immune-senescence, allergy, viral diseases (CMV, HBV, HCV), transfusion transmitted diseases.

Professional skills**Research:**

- Biostatistics; data analysis; clinical studies; systematic reviews, meta-analysis.
- Molecular biology techniques (cloning, sequencing, transfections, etc.); cell cultures (human primary cultures and neoplastic cells);

Clinical activity: Allergic diseases, Allergen Specific Immunotherapy (for allergic diseases); Severe asthma/nasal polyps/atopic dermatitis/urticaria treatment with biologics; desensitization procedures with chemotherapeutic agents of enzyme for replacement therapy. Therapeutic apheresis (plasma-exchange, erythrocyte-exchange; leucocyte-apheresis for autoimmune or metabolic diseases).

Participation in RCTs:

- GSK, Captain, trial code: 205715, started in 2016.
- Novartis Vibrant, trial code: QAW039A2314. Fevipirant, started in 2017.
- GSK, Nimble, ongoing (PI)

- GSK, Swift 2, ongoing (PI)

Recent grants:

- HORIZON EUROPE SEEDS. Titolo: Gestione sostenibile di scarti Agroalimentari come fonte Innovativa di biomateriali multifunzionali per la salute umana e l'Ambiente (G.A.I.A.), è stato ammesso a finanziamento con D.R. n. 1333 del 11/04/2022 (cofinanziamento a valere sui fondi del D.M. 737/2021). CUP: H91I21001590006

- Missione 4 "Istruzione e Ricerca" - Componente C2

Investimento 1.1, "Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN)"

Decreto Direttoriale n. 104 del 2 febbraio 2022, Avviso pubblico per la presentazione di Progetti di ricerca di Rilevante Interesse Nazionale (PRIN) da finanziare nell'ambito del PNRR

ATTO D'OBBLIGO E DI ACCETTAZIONE DEL DECRETO DI AMMISSIONE A FINANZIAMENTO DEL PROGETTO DI RICERCA DI RILEVANTE INTERESSE NAZIONALE (PRIN)

20228YERZP

Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial

List of publications

1: Ordak M, Canonica GW, Paoletti G, Brussino L, Carvalho D, Di Bona D. Meta-analysis in allergy-Statistical recommendations. Allergy. 2024 Feb 29. doi: 10.1111/all.16091. Epub ahead of print. PMID: 38425079.

2: Di Bona D, Carlucci P, Spataro F, Paoletti G, Cognet-Sicé J, Scurati S, Canonica GW. IR (index of reactivity)-house dust mite sublingual immunotherapy liquid formulation for allergic rhinoconjunctivitis: Systematic review and meta-analysis of randomized and nonrandomized studies. J Allergy Clin Immunol Glob. 2024 Jan 9;3(2):100208. doi: 10.1016/j.jacig.2024.100208. PMID: 38328804; PMCID: PMC10847924.

3: Ordak M, Canonica GW, Paoletti G, Brussino L, Carvalho D, Di Bona D. Statistical advice provided by ChatGPT regarding an accepted article in Allergy. Allergy. 2024 Mar;79(3):748-751. doi: 10.1111/all.15956. Epub 2023 Nov 20. PMID: 37985460.

4: Miniello A, Casella R, Loverre T, Aloia D, Di Bona D, Nettis E. An update on nonsteroidal anti-inflammatory drug-induced urticaria. Endocr Metab Immune Disord Drug Targets. 2023 Sep 7. doi: 10.2174/1871530323666230907112453. Epub ahead of print. PMID: 37691219.

5: Loverre T, Casella R, Miniello A, Di Bona D, Nettis E. Latex allergy - from discovery to component-resolved diagnosis. Endocr Metab Immune Disord Drug Targets. 2023 Sep 1. doi: 10.2174/1871530323666230901102131. Epub ahead of print. PMID: 37680164.

6: Ligotti ME, Calabrò A, Accardi G, Aiello A, Caruso C, Colomba C, Di Bona D, Duro G, Namboodiri AM, Tuttolomondo A, Pandey JP, Candore G. GM Allotypes and COVID-19. A Pilot Study Performed on Sicilian Patients. Transl Med UniSa. 2022 Dec 27;24(2):26-29. doi: 10.37825/2239-9747.1039. PMID: 37476201; PMCID:

PMC10354864.

7: Paoletti G, Costanzo G, Del Moro L, Spataro F, Carlucci P, Di Bona D. Editorial: pharmacotherapy and evidence-based medicine section. *Curr Opin Allergy Clin Immunol*. 2023 Aug 1;23(4):307-308. doi: 10.1097/ACI.0000000000000919. PMID: 37431549.

8: Spataro F, Carlucci P, Loverre T, Macchia L, Di Bona D. Hypersensitivity reaction during enzyme replacement therapy in lysosomal storage disorders. A systematic review of desensitization strategies. *Pediatr Allergy Immunol*. 2023 Jun;34(6):e13981. doi: 10.1111/pai.13981. PMID: 37366214.

9: Di Bona D, Carlucci P, Spataro F, Paoletti G, Heffler E, Pulkanen J, Macchia L, Giacco SD, Agache I, Jutel M, Schünemann HJ, Canonica GW. Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy. *Clin Exp Allergy*. 2023 Jun;53(6):610-625. doi: 10.1111/cea.14311. Epub 2023 Apr 3. PMID: 37012529.

10: Stefanizzi P, Ferorelli D, Scazzi FL, Di Lorenzo A, Martinelli A, Trinchera C, Moscara L, Miniello E, Di Bona D, Tafuri S. Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy). *Front Immunol*. 2023 Feb 27;14:1074246. doi: 10.3389/fimmu.2023.1074246. PMID: 36923411; PMCID: PMC10008905.

11: Barlaam A, Puccini A, Caiaffa MF, Di Bona D, Macchia L, Giangaspero A. Dermatomyositis in the Urban Context: When the One Health Paradigm Is Put into Practice. *Pathogens*. 2022 Nov 23;11(12):1396. doi: 10.3390/pathogens11121396. PMID: 36558730; PMCID: PMC9782833.

12: Ligotti ME, Aiello A, Accardi G, Calabrò A, Ciaccio M, Colomba C, Di Bona D, Lo Sasso B, Pojero F, Tuttolomondo A, Caruso C, Candore G, Duro G. Distribution of KIR Genes and Their HLA Ligands in Different Viral Infectious Diseases: Frequency Study in Sicilian Population. *Int J Mol Sci*. 2022 Dec 7;23(24):15466. doi: 10.3390/ijms232415466. PMID: 36555106; PMCID: PMC9779783.

13: Di Bona D, Miniello A, Nettis E. Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine. *Clin Mol Allergy*. 2022 Dec 12;20(1):13. doi: 10.1186/s12948-022-00179-8. PMID: 36503530; PMCID: PMC9742018.

14: Spataro F, Viggiani F, Macchia DG, Rollo V, Tummolo A, Suppressa P, Sabba' C, Rossi MP, Giliberti L, Satriano F, Nettis E, Di Bona D, Caiaffa MF, Fischetto R, Macchia L. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS). *Orphanet J Rare Dis*. 2022 Nov 3;17(1):402. doi: 10.1186/s13023-022-02556-7. PMID: 36329518; PMCID: PMC9635105.

15: Foti C, Calogiuri G, Nettis E, De Marco A, Stingeni L, Hansel K, Di Bona D, Carlucci P, Romita P, Barbaud A. Allergic contact dermatitis from vitamins: A systematic review. *Health Sci Rep*. 2022 Oct 3;5(6):e766. doi: 10.1002/hsr2.766. PMID: 36210883; PMCID: PMC9528950.

16: Minenna E, Chaoul N, Rossi MP, Giliberti L, Albanesi M, Nettis E, Barbaro MPF, Di Bona D, Caiaffa MF, Macchia L. Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis. *Postepy Dermatol Alergol.* 2022 Aug;39(4):816-818. doi: 10.5114/ada.2021.109586. Epub 2021 Oct 1. PMID: 36090719; PMCID: PMC9454356.

17: Albanesi M, Zurlo M, Magistà S, Chaoul N, Minenna E, Satriano F, Di Bona D, Nettis E, Caiaffa MF, Macchia L. Chronic urticaria reveals JAK2V617F positive essential thrombocythemia. *Postepy Dermatol Alergol.* 2022 Jun;39(3):642-644. doi: 10.5114/ada.2021.110252. Epub 2021 Oct 25. PMID: 35950137; PMCID: PMC9326935.

18: Di Bona D, Spataro F, Carlucci P, Paoletti G, Canonica GW. Severe asthma and personalized approach in the choice of biologic. *Curr Opin Allergy Clin Immunol.* 2022 Aug 1;22(4):268-275. doi: 10.1097/ACI.0000000000000829. Epub 2022 Jul 2. PMID: 35779061.

19: Paoletti G, Pepys J, Casini M, Di Bona D, Heffler E, Goh CYY, Price DB, Canonica GW. Biologics in severe asthma: the role of real-world evidence from registries. *Eur Respir Rev.* 2022 Jun 7;31(164):210278. doi: 10.1183/16000617.0278-2021. PMID: 35675922; PMCID: PMC9489006.

20: Nettis E, Brussino L, Patella V, Bonzano L, Detoraki A, Di Leo E, Sirufo MM, Caruso C, Lodi Rizzini F, Conte M, Yacoub MR, Triggiani M, Ridolo E, Macchia L, Rolla G, Brancaccio R, De Paulis A, Spadaro G, Di Bona D, D'Uggento AM, Ginaldi L, Gaeta F, Nucera E, Jaubashi K, Villalta D, Dagna L, Ciotta D, Pucciarini F, Bagnasco D, Celi G, Chieco Bianchi F, Cosmi L, Costantino MT, Crivellaro MA, D'Alò S, Del Biondo P, Del Giacco S, Di Gioacchino M, Di Pietro L, Favero E, Gangemi S, Guarnieri G, Heffler E, Leto Barone MS, Lombardo C, Losa F, Matucci A, Minciullo PL, Parronchi P, Passalacqua G, Pucci S, Rossi O, Salvati L, Schiappoli M, Senna G, Vianello A, Vultaggio A, Baoran Y, Incorvaia C, Canonica GW. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. *Clin Mol Allergy.* 2022 May 19;20(1):6. doi: 10.1186/s12948-022-00171-2. PMID: 35590407; PMCID: PMC9121619.

21: De Angelis E, Di Bona D, Pilolli R, Loiodice R, Luparelli A, Giliberti L, D'Uggento AM, Rossi MP, Macchia L, Monaci L. In Vivo and In Vitro Assessment and Proteomic Analysis of the Effectiveness of Physical Treatments in Reducing Allergenicity of Hazelnut Proteins. *Nutrients.* 2022 Feb 19;14(4):874. doi: 10.3390/nu14040874. PMID: 35215523; PMCID: PMC8875159.

1: Bagnasco D, Paggiaro P, Latorre M, Folli C, Testino E, Bassi A, Milanese M, Heffler E, Manfredi A, Riccio AM, De Ferrari L, Blasi F, Canevari RF, Canonica GW, Passalacqua G; SANI (Severe Asthma Network Italy); Severe Asthma Network Italy. Severe asthma: One disease and multiple definitions. *World Allergy Organ J.* 2021 Nov 19;14(11):100606. doi: 10.1016/j.waojou.2021.100606. PMID: 34871335; PMCID: PMC8609160.

22: Di Bona D, Crimi C, D'Uggento AM, Benfante A, Caiaffa MF, Calabrese C,

Campisi R, Carpagnano GE, Ciotta D, D'Amato M, Pelaia C, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Ribecco N, Spadaro G, Valenti G, Vatrella A, Crimi N, Macchia L. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis. *Clin Exp Allergy*. 2022 Feb;52(2):312-323. doi: 10.1111/cea.14026. Epub 2021 Oct 16. PMID: 34608696.

23: Di Bona D, Paoletti G, Chu DK, Pepys J, Macchia L, Heffler E, Canonica GW. Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis. *Clin Transl Allergy*. 2021 Jun 14;11(4):e12033. doi: 10.1002/clt2.12033. PMID: 34141180; PMCID: PMC8203181.

24: Nettis E, Masciopinto L, Di Leo E, De Candia N, Albanesi M, Di Bona D, Quaranta N, Macchia L. Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis. *Clin Mol Allergy*. 2021 Jun 16;19(1):9. doi: 10.1186/s12948-021-00144-x. PMID: 34134707; PMCID: PMC8207639.

25: Pini L, Giordani J, Concoreggi C, Zanardini E, Pini A, Perger E, Bargagli E, Di Bona D, Ciarfaglia M, Tantucci C. Effects of short-term exposure to particulate matter on emergency department admission and hospitalization for asthma exacerbations in Brescia district. *J Asthma*. 2021 Jun 14:1-8. doi: 10.1080/02770903.2021.1929310. Epub ahead of print. PMID: 33980121.

26: Pojero F, Candore G, Caruso C, Di Bona D, Groneberg DA, Ligotti ME, Accardi G, Aiello A. The Role of Immunogenetics in COVID-19. *Int J Mol Sci*. 2021 Mar 5;22(5):2636. doi: 10.3390/ijms22052636. PMID: 33807915; PMCID: PMC7961811.

27: Di Bona D, Nettis E, Bilancia M, Ridolo E, Minenna E, Nizi MC, Albanesi M, Caiaffa MF, Macchia L. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study. *J Allergy Clin Immunol Pract*. 2021 Jun;9(6):2482-2485.e2. doi: 10.1016/j.jaip.2021.02.044. Epub 2021 Mar 4. PMID: 33677081.

28: Pini L, Giordani J, Gardini G, Concoreggi C, Pini A, Perger E, Vizzardi E, Di Bona D, Cappelli C, Ciarfaglia M, Tantucci C. Emergency department admission and hospitalization for COPD exacerbation and particulate matter short-term exposure in Brescia, a highly polluted town in northern Italy. *Respir Med*. 2021 Apr;179:106334. doi: 10.1016/j.rmed.2021.106334. Epub 2021 Feb 16. PMID: 33640663.

29: Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. *World Allergy Organ J*. 2021 Jan 27;14(2):100509. doi: 10.1016/j.waojou.2021.100509. PMID: 33598095; PMCID: PMC7846931.

30: Paoletti G, Di Bona D, Chu DK, Firinu D, Heffler E, Agache I, Jutel M,

Klimek L, Pfaar O, Mösges R, DunnGalvin A, Genuneit J, Hoffmann HJ, Canonica GW.

Allergen immunotherapy: The growing role of observational and randomized trial "Real-World Evidence". *Allergy*. 2021 Sep;76(9):2663-2672. doi: 10.1111/all.14773. PMID: 33583050.

31: Magistà S, Albanesi M, Chaoul N, Di Bona D, Di Leo E, Nettis E, Caiaffa MF, Macchia L. Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management. *Clin Mol Allergy*. 2020 Nov 15;18(1):21. doi: 10.1186/s12948-020-00136-3. PMID: 33292334; PMCID: PMC7667750.

32: Di Bona D, Malovini A, Accardi G, Aiello A, Candore G, Ferrario A, Ligotti ME, Maciag A, Puca AA, Caruso C. Taste receptor polymorphisms and longevity: a systematic review and meta-analysis. *Aging Clin Exp Res*. 2021 Sep;33(9):2369-2377. doi: 10.1007/s40520-020-01745-3. Epub 2020 Nov 10. PMID: 33170488; PMCID: PMC8429150.

33: Di Bona D, Minenna E, Albanesi M, Nettis E, Caiaffa MF, Macchia L. Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort. *Pulm Pharmacol Ther*. 2020 Oct;64:101974. doi: 10.1016/j.pupt.2020.101974. Epub 2020 Nov 1. PMID: 33137516.

34: Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, D'Amato M, De Ferrari L, Di Marco F, Imeri G, Di Bona D, Gilardenghi A, Guida G, Lombardi C, Milanese M, Nicolini A, Riccio AM, Rolla G, Santus P, Senna G, Passalacqua G. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. *Respir Med*. 2020 Sep;171:106080. doi: 10.1016/j.rmed.2020.106080. Epub 2020 Jul 3. PMID: 32917354.

55: Bilancia M, Pasculli G, Di Bona D. A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy. *PLoS One*. 2020 May 14;15(5):e0232753. doi: 10.1371/journal.pone.0232753. PMID: 32407326; PMCID: PMC7224467.

36: Di Bona D, Nettis E, Minenna E, Lovecchio A, Paolino D, Cristina Nizi M, Albanesi M, Ridolo E, Filomena Caiaffa M, Macchia L. Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study. *Allergy*. 2020 Oct;75(10):2681-2684. doi: 10.1111/all.14341. Epub 2020 May 25. PMID: 32348578.

37: Tuttolomondo A, Di Raimondo D, Vasto S, Casuccio A, Colomba C, Norrito RL, Di Bona D, Arnao V, Siciliano L, Cascio A, Pinto A; KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group. Protective and causative killer Ig-like receptor (KIR) and metalloproteinase genetic patterns associated with Herpes simplex virus 1 (HSV-1) encephalitis occurrence. *J Neuroimmunol*. 2020 Jul 15;344:577241. doi: 10.1016/j.jneuroim.2020.577241. Epub 2020 Apr 14. PMID: 32334204.

38: Di Girolamo A, Albanesi M, Loconte F, Di Bona D, Caiaffa MF, Macchia L. Desensitization in Iron Product Allergy. *Acta Haematol*. 2020;143(5):496-499.

doi: 10.1159/000503768. Epub 2020 Mar 17. PMID: 32182610.

39: Di Bona D, Bilancia M, Albanesi M, Caiaffa MF, Macchia L. Cost-effectiveness of grass pollen allergen immunotherapy in adults. *Allergy*. 2020 Sep;75(9):2319-2329. doi: 10.1111/all.14246. Epub 2020 Mar 12. PMID: 32096242.

40: Di Bona D, Magistà S, Masciopinto L, Lovecchio A, Loiodice R, Bilancia M, Albanesi M, Caiaffa MF, Nettis E, Macchia L; AIT Study Group. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study. *Respir Med*. 2020 Jan;161:105843. doi: 10.1016/j.rmed.2019.105843. Epub 2019 Nov 20. PMID: 31778936.

41: Di Bona D, Pandey JP, Aiello A, Bilancia M, Candore G, Caruso C, Colomba C, Duro G, Ligotti ME, Macchia L, Rizzo S, Accardi G. The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans. *Immunology*. 2020 Feb;159(2):178-182. doi: 10.1111/imm.13133. Epub 2019 Nov 12. PMID: 31613998; PMCID: PMC6954734.

42: Di Bona D, Albanesi M, Macchia L. Is immunotherapy with fungal vaccines effective? *Curr Opin Allergy Clin Immunol*. 2019 Dec;19(6):646-653. doi: 10.1097/ACI.0000000000000582. PMID: 31403481.

43: Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A, Cippitelli M. The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress. *Cancers (Basel)*. 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810. PMID: 31212703; PMCID: PMC6627474.

44: Tuttolomondo A, Di Raimondo D, Pecoraro R, Casuccio A, Di Bona D, Aiello A, Accardi G, Arnao V, Clemente G, Corte VD, Maida C, Simonetta I, Caruso C, Squatrito R, Pinto A; KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute ischemic stroke. *J Neuroinflammation*. 2019 Apr 17;16(1):88. doi: 10.1186/s12974-019-1469-5. PMID: 30995924; PMCID: PMC6471781.

45: Chaoul N, Albanesi M, Giliberti L, Rossi MP, Nettis E, Di Bona D, Caiaffa MF, Macchia L. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects. *Int Arch Allergy Immunol*. 2019;179(1):37-42. doi: 10.1159/000496436. Epub 2019 Mar 28. PMID: 30921804.

46: Accardi G, Aprile S, Candore G, Caruso C, Cusimano R, Cristaldi L, Di Bona D, Duro G, Galimberti D, Gambino CM, Ligotti ME, Mazzucco W, Vasto S, Aiello A. Genotypic and Phenotypic Aspects of Longevity: Results from a Sicilian Survey and Implication for the Prevention and Treatment of Age-related Diseases. *Curr Pharm Des*. 2019;25(3):228-235. doi: 10.2174/1381612825666190313115233. PMID: 30864497.

47: Albanesi M, Pasculli C, Giliberti L, Rossi MP, Di Bona D, Caiaffa MF, Macchia L. Immunological characterization of onion (*Allium cepa*) allergy. *Postepy Dermatol Alergol*. 2019 Feb;36(1):98-103. doi: 10.5114/ada.2019.82829. Epub 2019 Feb 22. PMID: 30858787; PMCID: PMC6409889.

48: Aiello A, Accardi G, Candore G, Caruso C, Colomba C, Di Bona D, Duro G, Gambino CM, Ligotti ME, Pandey JP. Role of Immunogenetics in the Outcome of HCMV

Infection: Implications for Ageing. *Int J Mol Sci.* 2019 Feb 5;20(3):685. doi: 10.3390/ijms20030685. PMID: 30764515; PMCID: PMC6386818.

49: Albanesi M, Di Girolamo A, Aresta V, Rossi MP, Giliberti L, Perrone T, Di Bona D, Caiaffa MF, Specchia G, Macchia L. Delayed allergy to acyclovir revealed by lymphocyte proliferation test. *Postepy Dermatol Alergol.* 2018

Oct;35(5):527-529. doi: 10.5114/ada.2018.77244. Epub 2018 Jul 19. PMID: 30429714; PMCID: PMC6232537.

50: Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, Di Bona D, Pfaar O, Ahlbeck L, Akdis M, Weinfeld D, Contreras-Verduzco FA, Pedroza-Melendez A, Skaarup SH, Lee SM, Cardell LO, Schmid JM, Westin U, Dollner R, Kündig TM. Intralymphatic Immunotherapy: Update and Unmet Needs. *Int Arch Allergy Immunol.* 2019;178(2):141-149. doi: 10.1159/000493647. Epub 2018 Nov

2. PMID: 30391954.

51: Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, Macchia L. Rapid desensitization for brentuximab vedotin (Adceteris[®]) allergy: a case report. *Clin Mol Allergy.* 2018 Oct 29;16:22. doi:

10.1186/s12948-018-0100-0. PMID: 30386181; PMCID: PMC6205792.

52: Aiello A, Candore G, Accardi G, Caruso C, Colomba C, Duro G, Gambino CM, Ligotti ME, Di Bona D. Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases. *Curr Pharm Des.* 2018;24(26):3113-3122. doi: 10.2174/1381612824666180911123249. PMID:

30205795.

53: Di Bona D, Frisenda F, Albanesi M, Di Lorenzo G, Caiaffa MF, Macchia L. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. *Clin Exp Allergy.* 2018 Nov;48(11):1391-1401. doi:

10.1111/cea.13242. Epub 2018 Sep 4. PMID: 30079619.

54: Albanesi M, Sinisi A, Frisenda F, Di Bona D, Caiaffa MF, Macchia L. Importance of Specific IgE/Total IgE Ratio in Disambiguating Amoxicillin Allergy Diagnosis in a Real-Life Setting. *Int Arch Allergy Immunol.* 2018;177(2):167-169. doi: 10.1159/000489705. Epub 2018 Jun 19. PMID: 29920499.

55: Albanesi M, Carluccio P, Nico A, Giliberti L, Di Bona D, Caiaffa MF, Specchia G, Macchia L. A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. *Postepy Dermatol Alergol.* 2018

Apr;35(2):222-224. doi: 10.5114/ada.2018.75249. Epub 2018 Apr 24. PMID: 29760627; PMCID: PMC5949556.

56: Tuttolomondo A, Colomba C, Di Bona D, Casuccio A, Di Raimondo D, Clemente G,

Arnao V, Pecoraro R, Ragonese P, Aiello A, Accardi G, Maugeri R, Maida C, Simonetta I, Della Corte V, Iacopino DG, Caruso C, Cascio A, Pinto A; KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis. *Oncotarget*. 2018 Apr 3;9(25):17523-17532. doi: 10.18632/oncotarget.24778. PMID: 29707126; PMCID: PMC5915134.

57: Gambino CM, Di Bona D, Aiello A, Carru C, Duro G, Guggino G, Ferrante A, Zinellu A, Caruso C, Candore G, Accardi G. HLA-C1 ligands are associated with increased susceptibility to systemic lupus erythematosus. *Hum Immunol*. 2018 Mar;79(3):172-177. doi: 10.1016/j.humimm.2018.01.005. Epub 2018 Feb 2. PMID: 29395276.

58: Albanesi M, Nico A, Sinisi A, Giliberti L, Rossi MP, Rossini M, Kourtis G, Rucco AS, Loconte F, Muolo L, Zurlo M, Di Bona D, Caiaffa MF, Macchia L. A 13-year real-life study on efficacy, safety and biological effects of *Vespula* venom immunotherapy. *Clin Mol Allergy*. 2018 Jan 18;16:2. doi: 10.1186/s12948-017-0079-y. PMID: 29375272; PMCID: PMC5774115.

59: Di Lorenzo G, Di Bona D, Belluzzo F, Macchia L. Immunological and non-immunological mechanisms of allergic diseases in the elderly: biological and clinical characteristics. *Immun Ageing*. 2017 Dec 20;14:23. doi: 10.1186/s12979-017-0105-4. PMID: 29296117; PMCID: PMC5738884.

60: Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C, Kourtis G, Rucco AS, Nico A, Albanesi M, Giliberti L, D'Elia L, Caiaffa MF, Macchia L. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. *Respir Med*. 2017 Sep;130:55-60. doi: 10.1016/j.rmed.2017.07.013. Epub 2017 Jul 19. PMID: 29206634.

61: Di Bona D, Accardi G, Aiello A, Bilancia M, Candore G, Colomba C, Caruso C, Duro G, Gambino CM, Macchia L, Pandey JP. Association between γ marker, human leucocyte antigens and killer immunoglobulin-like receptors and the natural course of human cytomegalovirus infection: a pilot study performed in a Sicilian population. *Immunology*. 2018 Apr;153(4):523-531. doi: 10.1111/imm.12855. Epub 2017 Dec 11. PMID: 29067686; PMCID: PMC5838424.

62: Aiello A, Di Bona D, Candore G, Carru C, Zinellu A, Di Miceli G, Nicosia A, Gambino CM, Ruisi P, Caruso C, Vasto S, Accardi G. Targeting Aging with Functional Food: Pasta with *Opuntia* Single-Arm Pilot Study. *Rejuvenation Res*. 2018 Jun;21(3):249-256. doi: 10.1089/rej.2017.1992. Epub 2017 Oct 10. PMID: 28851251.

63: Colomba C, Cascio A, Caruso C, Trizzino M, Gioè C, Guadagnino G, Tuttolomondo A, Pinto A, Saracino A, Angarano G, Di Bona D; in rappresentanza del KIRIIND (Kir Infectious-Inflammatory Diseases) Collaborative Group. Ruolo dell'interazione NK/KIR nella storia naturale delle infezioni virali [Role of combination NK/KIRs in the natural history of viral infections.]. *Recenti Prog Med*. 2017 Jul-Aug;108(7):333-337. Italian. doi: 10.1701/2731.27839. PMID: 28845855.

- 64: Di Lorenzo G, Leto-Barone MS, La Piana S, Plaia A, Di Bona D. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. *Int Forum Allergy Rhinol*. 2017 Jul;7(7):660-669. doi: 10.1002/alr.21946. Epub 2017 May 23. PMID: 28544523.
- 65: Colomba C, Trizzino M, Giammanco A, Bonura C, Di Bona D, Tolomeo M, Cascio A. Israeli Spotted Fever in Sicily. Description of two cases and minireview. *Int J Infect Dis*. 2017 Aug;61:7-12. doi: 10.1016/j.ijid.2017.04.003. Epub 2017 Apr 10. PMID: 28408252.
- 66: Tuttolomondo A, Casuccio A, Guercio G, Maida C, Del Cuore A, Di Raimondo D, Simonetta I, Di Bona D, Pecoraro R, Della Corte V, Gulotta E, Gulotta G, Pinto A. Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome. *Cardiovasc Diabetol*. 2017 Jan 6;16(1):2. doi: 10.1186/s12933-016-0483-5. PMID: 28056981; PMCID: PMC5217198.
- 67: Tuttolomondo A, Di Raimondo D, Bellia C, Clemente G, Pecoraro R, Maida C, Simonetta I, Vassallo V, Di Bona D, Gulotta E, Ciaccio M, Pinto A. Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites. *PLoS One*. 2016 Dec 12;11(12):e0165443. doi: 10.1371/journal.pone.0165443. PMID: 27941973; PMCID: PMC5152809.
- 68: Di Bona D, Albanesi M, Giliberti LA, Nico A, Rossi MP, Caiaffa MF, Macchia L. Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera). *J Allergy Clin Immunol Pract*. 2017 May-Jun;5(3):821-822. doi: 10.1016/j.jaip.2016.09.044. Epub 2016 Nov 23. PMID: 27888036.
- 69: Colomba C, Trizzino M, Gioè C, Di Bona D, Mularoni A, Cascio A. HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation? *IDCases*. 2016 Sep 29;6:74-76. doi: 10.1016/j.idcr.2016.09.017. PMID: 27752472; PMCID: PMC5066192.
- 70: Di Bona D, Plaia A, Di Lorenzo G. Reply. *J Allergy Clin Immunol*. 2016 Jul;138(1):315-317.e2. doi: 10.1016/j.jaci.2016.01.041. Epub 2016 Apr 12. PMID: 27084401.
- 71: Tuttolomondo A, Di Raimondo D, Pecoraro R, Maida C, Arnao V, Della Corte V, Simonetta I, Corpora F, Di Bona D, Maugeri R, Iacopino DG, Pinto A. Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial. *Medicine (Baltimore)*. 2016 Mar;95(13):e3186. doi: 10.1097/MD.0000000000003186. PMID: 27043681; PMCID: PMC4998542.
- 72: Di Bona D, Cefalù AB, Scirè E, Lima GM, Rizzo CM, Giammanco A, Barbagallo CM, Averna MR, Rizzo S, Caruso C. Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitis. *Transfusion*. 2016 Mar;56(3):755-60. doi: 10.1111/trf.13400. Epub

2015 Nov 4. PMID: 26536493.

73: Tuttolomondo A, Casuccio A, Buttà C, Pecoraro R, Di Raimondo D, Della Corte V, Arnao V, Clemente G, Maida C, Simonetta I, Miceli G, Lucifora B, Cirrincione A, Di Bona D, Corpora F, Maugeri R, Iacopino DG, Pinto A. Mediterranean Diet in patients with acute ischemic stroke: Relationships between Mediterranean Diet score, diagnostic subtype, and stroke severity index. *Atherosclerosis*. 2015 Nov;243(1):260-7. doi: 10.1016/j.atherosclerosis.2015.09.017. Epub 2015 Sep 11. PMID: 26409625.

74: Corrao S, Di Bona D, Di Lorenzo G. Efficacy but not effectiveness of sublingual immunotherapy for grass pollen allergy: Time to avoid waste in health-care expenditure. *Eur J Intern Med*. 2015 Oct;26(8):561-2. doi: 10.1016/j.ejim.2015.08.018. Epub 2015 Sep 14. PMID: 26377975.

75: Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2015 Aug;175(8):1301-9. doi: 10.1001/jamainternmed.2015.2840. PMID: 26120825.

76: Di Bona D, Plaia A, Di Lorenzo G. Knowledge of the literature is crucial for meta-analyses. *J Allergy Clin Immunol*. 2015 Jan;135(1):293-4. doi: 10.1016/j.jaci.2014.08.047. Epub 2014 Oct 24. PMID: 25441648.

77: Di Bona D, Scafidi V, Plaia A, Colomba C, Nuzzo D, Occhino C, Tuttolomondo A, Giammanco G, De Grazia S, Montalto G, Duro G, Cippitelli M, Caruso C. HLA and killer cell immunoglobulin-like receptors influence the natural course of CMV infection. *J Infect Dis*. 2014 Oct 1;210(7):1083-9. doi: 10.1093/infdis/jiu226. Epub 2014 Apr 15. PMID: 24737799.

78: Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association between genetic variations in the insulin/insulin-like growth factor (Igf-1) signaling pathway and longevity: a systematic review and meta-analysis. *Curr Vasc Pharmacol*. 2014;12(5):674-81. doi: 10.2174/1570161111666131218152807. PMID: 24350933.

79: Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association of Klotho polymorphisms with healthy aging: a systematic review and meta-analysis. *Rejuvenation Res*. 2014 Apr;17(2):212-6. doi: 10.1089/rej.2013.1523. Epub 2014 Apr 11. PMID: 24164579.

80: Di Bona D, Plaia A, Di Lorenzo G. Reply: To PMID 23021885. *J Allergy Clin Immunol*. 2013 Aug;132(2):508-10. doi: 10.1016/j.jaci.2013.04.058. Epub 2013 Jun 20. PMID: 23791511.

81: Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. *J Allergy Clin Immunol*. 2012 Nov;130(5):1097-1107.e2. doi: 10.1016/j.jaci.2012.08.012. Epub 2012 Sep 27. PMID: 23021885.

82: Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, Bono R, Quintini G, Caruso C. Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange. *Blood Transfus.* 2012 Oct;10(4):521-32. doi: 10.2450/2012.0122-11. Epub 2012 Jun 27. PMID: 22790258; PMCID: PMC3496241.

83: Colomba C, Lalicata F, Siracusa L, Saporito L, Di Bona D, Giammanco G, De Grazia S, Titone L. Malattia da Citomegalovirus nell'ospite immunocompetente. Considerazioni clinico-immunologiche [Cytomegalovirus infection in immunocompetent patients. Clinical and immunological considerations]. *Infez Med.* 2012 Mar;20(1):12-5. Italian. PMID: 22475655.

84: Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis.* 2012;29(4):751-9. doi: 10.3233/JAD-2012-111838. PMID: 22356904.

85: Di Lorenzo G, Pacor ML, Amodio E, Leto-Barone MS, La Piana S, D'Alcamo A, Ditta V, Martinelli N, Di Bona D. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. *Int Arch Allergy Immunol.* 2011;155(3):263-70. doi: 10.1159/000320050. Epub 2011 Feb 2. PMID: 21293145.

86: Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. *J Allergy Clin Immunol.* 2010 Sep;126(3):558-66. doi: 10.1016/j.jaci.2010.06.013. Epub 2010 Aug 1. PMID: 20674964.

87: Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. *Rejuvenation Res.* 2010 Apr-Jun;13(2-3):301-13. doi: 10.1089/rej.2009.0993. PMID: 20462385.

88: Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammà C, Lio D, Caruso C. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. *Brain Res Rev.* 2009 Oct;61(2):60-8. doi: 10.1016/j.brainresrev.2009.05.001. Epub 2009 May 13. PMID: 19445962.

89: Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bona D, Forte GI, Lio D, Listi F, Scola L, Vasto S. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. *Cancer Immunol Immunother.* 2009 Dec;58(12):1919-33. doi: 10.1007/s00262-009-0658-y. Epub 2009 Feb 17. PMID: 19221747.

90: Di Bona D, Vasto S, Capurso C, Christiansen L, Deiana L, Franceschi C, Hurme M, Mocchegiani E, Rea M, Lio D, Candore G, Caruso C. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. *Ageing Res Rev.* 2009 Jan;8(1):36-42. doi: 10.1016/j.arr.2008.09.001. Epub 2008 Sep 27.

PMID: 18930842.

91: Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. Inflammation and prostate cancer. *Future Oncol.* 2008 Oct;4(5):637-45. doi: 10.2217/14796694.4.5.637. PMID: 18922121.

92: Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. *Brain Res Rev.* 2008 Nov;59(1):155-63. doi: 10.1016/j.brainresrev.2008.07.003. Epub 2008 Jul 21. PMID: 18675847.

93: Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C. Inflammation, ageing and cancer. *Mech Ageing Dev.* 2009 Jan-Feb;130(1-2):40-5. doi: 10.1016/j.mad.2008.06.003. Epub 2008 Jul 10. PMID: 18671998.

94: Vasto S, Candore G, Listi F, Balistreri CR, Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C. Inflammation, genes and zinc in Alzheimer's disease. *Brain Res Rev.* 2008 Jun;58(1):96-105. doi: 10.1016/j.brainresrev.2007.12.001. Epub 2007 Dec 8. PMID: 18190968.

95: Di Bona D, Cippitelli M, Fionda C, Cammà C, Licata A, Santoni A, Craxì A. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. *J Hepatol.* 2006 Aug;45(2):271-9. doi: 10.1016/j.jhep.2006.01.037. Epub 2006 Mar 9. PMID: 16595158.

96: Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxì A. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology.* 2006 Jan;43(1):64-71. doi: 10.1002/hep.20983. PMID: 16374856.

97: Cammà C, Di Marco V, Orlando A, Sandonato L, Casaril A, Parisi P, Alizzi S, Sciarrino E, Virdone R, Pardo S, Di Bona D, Licata A, Latteri F, Cabibbo G, Montalto G, Latteri MA, Nicoli N, Craxì A; Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. *J Hepatol.* 2005 Apr;42(4):535-40. doi: 10.1016/j.jhep.2004.11.042. PMID: 15868653.

98: Cippitelli M, Fionda C, Di Bona D, Piccoli M, Frati L, Santoni A. Hyperthermia enhances CD95-ligand gene expression in T lymphocytes. *J Immunol.* 2005 Jan 1;174(1):223-32. doi: 10.4049/jimmunol.174.1.223. PMID: 15611244.

99: Bruno S, Cammà C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucci C, Di Bona D, Colombo M, Craxì A, Mondelli MU, Pinzello G. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol.* 2004 Sep;41(3):474-81. doi: 10.1016/j.jhep.2004.05.012. PMID: 15336451.

- 100: Cammà C, Di Bona D, Craxì A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. *Curr Pharm Des.* 2004;10(17):2123-30. doi: 10.2174/1381612043384321. PMID: 15279551.
- 101: Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxì A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology.* 2004 Feb;39(2):333-42. doi: 10.1002/hep.20073. PMID: 14767986.
- 102: Craxì A, Di Bona D, Cammà C. Interferon-alpha for HBeAg-positive chronic hepatitis B. *J Hepatol.* 2003;39 Suppl 1:S99-105. doi: 10.1016/s0168-8278(03)00154-5. PMID: 14708686.
- 103: Licata A, Di Bona D, Schepis F, Shahied L, Craxì A, Cammà C. When and how to treat acute hepatitis C? *J Hepatol.* 2003 Dec;39(6):1056-62. doi: 10.1016/s0168-8278(03)00461-6. PMID: 14642626.
- 104: Cippitelli M, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, Santoni A. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms. *J Immunol.* 2003 May 1;170(9):4578-92. doi: 10.4049/jimmunol.170.9.4578. PMID: 12707336.
- 105: Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M, Frati L, Santoni A. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. *J Immunol.* 2002 Feb 1;168(3):1154-66. doi: 10.4049/jimmunol.168.3.1154. PMID: 11801650.
106. Cippitelli M, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, Santoni A. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms. *J Immunol.* 2003 May 1;170(9):4578-92.
107. Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M, Frati L, Santoni A. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. *J Immunol.* 2002 Feb 1;168(3):1154-66.
108. Di Bona D, Montalto G, Clemenza L, Bascone F, Accardo P, Bellavia D, Craxì A, Brai M. Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases. *Clin Exp Immunol.* 1998 Oct;114(1):102-5.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV